27 results about "Connexin" patented technology

The invention discloses a method for promoting ovulation of sexual maturity zebrafish by using Gap27, and relates to the technical field of artificial breeding of fish, a gap connecting protein inhibitor Gap27 is applied to ovulation induction of zebrafish, an intercellular communication network in follicles is accurately intervened, the problem of asynchronous ovulation is solved, and in the final stage of maturation of oocytes, ovulation of sexual maturity zebrafish is promoted. Close substance and information exchange is carried out among follicular granule cells through a gap connecting channel formed by connecting protein Cx43, and Gap27 is used as a specific peptide fragment, can simulate an extracellular ring structure of Cx43, and competitively binds with Cx43 on an adjacent cell membrane, so that formation and functions of the gap connecting channel are physically blocked, and the follicular granule cells are separated from each other. When ovarian tissues of sexually mature female fish are exposed in a Gap27 solution, the transmission of inhibitory signals from granular cells to oocytes can be effectively interrupted, the rupture of nuclear membranes of the cells is promoted, and the final maturation process is completed.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

This invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The invention further relates to the use of the AAV vector in the treatment of hereditary hearing loss.

The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, optionally for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding a connexin 26 (CX26). The invention also relates to the use of said AAV vector in the treatment of hereditary hearing loss.

The present invention relates to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, in rescuing or restoring retinal function, rescuing or restoring retinal structure, and / or rescuing or restoring choroidal structure and / or function in chronic retinal disorders and other disorders.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a myocardial targeted engineered extracellular vesicle as well as a preparation method and application thereof. The invention provides an engineered extracellular vesicle. The engineered extracellular vesicle is an engineered extracellular vesicle subjected to overexpression modification of gap junction protein alpha 1; the amino acid sequence of the gap connecting protein alpha 1 is shown as SEQ ID NO. 1. The engineered extracellular vesicles are modified by expression gap connecting protein alpha1, and compared with a control, the engineered extracellular vesicles modified by the gap connecting protein alpha1 are more ingested by myocardial cells, have higher heart targeting performance and can provide targeting drug carriers for patients with heart diseases. The invention provides a new drug research and development approach and means for clinical treatment of heart failure or myocardial injury, also provides a heart targeted modification tool for industrial research and development and basic scientific research users, and has very important medicinal value.

The present invention relates to the use of a direct antibody, with a high degree of affinity and specificity, against the extracellular domain of the hemichannels formed by connexin 26 (Cx26, encoded by GJB2), connexin 30 (Cx30, encoded by GJB6) and / or connexin 32 (Cx32, encoded by GJB1), to treat brain tumours and epilepsy correlated thereto or to reduce or inhibit the development thereof.

The invention relates to a connexin-related kinase 1 (AAK1) inhibitor of a compound shown in a general formula (I), a preparation method thereof and application of the connexin-related kinase 1 (AAK1) inhibitor in medicine.

During aging, egg cells exhibit gradual loss of adherin complexes. The absence of connexin ultimately results in premature separation of sister staining monomers, resulting in aneuploidy. The inventors have designed an artificial adhesion system that binds staining monomers or chromosomes by forming complexes, thereby reducing the phenomena of premature separation of age-related sister staining monomers, e.g., in egg cells. The artificial adhesion system is a complex, and the aneuploidy risk is reduced by binding chromosomes or dyeing monomers. The complex comprises (I) one or more first proteins and (II) one or more second proteins wherein: (I) the first protein and (II) the second protein each comprise (i) a chromatin binding component, (ii) a protein binding region located at the N-terminus of the chromatin binding component, (Hi) a protein binding region located at the C-terminus of the chromatin binding component. The invention also includes nucleic acid molecules encoding the complexes. In addition, several in vitro methods associated with the complexes or nucleic acid molecules encoding said complexes also constitute part of the invention.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

Disclosed herein are methods and materials for treating myocarditis with gene therapy. In some cases, disclosed herein are methods and material for treating myocarditis in a subject in need thereof comprising administering to the subject an effective amount of a vector comprising a nucleic acid sequence encoding a connexin 43 polypeptide operably linked to a promoter active in cardiac muscle tissue. Also disclosed herein are methods of treating myocarditis by administering to a subject an agent that increases the level of a connexin 43 encoding nucleic acid molecule or connexin 43 polypeptide.

The present disclosure provides compositions and methods for treating osteosarcoma, such as osteosarcoma in a patient who has previously received at least one first-tier osteosarcoma treatment but has failed treatment. The methods comprise promoting the opening of Cx43 hemichannels in bone cells by, for example, using a composition comprising an anticonnexin 43 antibody.

The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.

The invention relates to the technical field of biology, and provides an application of a connexin signal channel in regulating and controlling the body weight and the body shape of worker bees. According to the invention, a cascade regulation pathway of Jhe-JH-Titin in bees is disclosed for the first time, which indicates that Jhe (juvenile hormone esterase) regulates JH (juvenile hormone) and further regulates the expression of Titin (connexin) to influence the growth and development of bees, and finally regulates the body type and weight of worker bees of bees. By means of the method, the purposes of regulating and controlling the birth weight and the body type of worker bees can be achieved. According to the method, molecular breeding work is carried out by adopting the regulation and control effect of the Jhe-JH-Titin pathway on the body type of the bees, the traditional breeding period can be shortened, and the breeding target of improving the body type of the bees can be rapidly achieved. The method is simple, convenient, easy to operate and short in breeding period, the body length of worker bees can be rapidly increased only through one generation, the breeding cost can be effectively reduced, and the method has important application and popularization value for bee breeding.

Methods for identifying compounds that positively regulate connexin 43 hemichannels.

In accordance with various aspects of the present disclosure, the disclosure relates to a method of treating cancer comprising (a) administering to a subject an anti-tight junction protein-1 antibody; (b) determining a PRO-C3 level in a test sample from the subject; and (c) comparing the level of PRO-C3 in the test sample to the level of PRO-C3 in a control sample. In some aspects, if the level of PRO-C3 in the test sample is not reduced relative to the level of PRO-C3 in the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is increased. In some aspects, if the level of PRO-C3 in the test sample is reduced relative to the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is not increased.

The inventions relate to compounds, compositions and kits comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and new and improved methods comprising systemic and topical administration of such modulators for the treatment of ocular and dermatological diseases, disorders and conditions, including ocular and dermatological diseases, disorders and conditions characterized at least in part by inflammasome-mediated inflammationb.

The inventions relate to compounds, compositions and kits comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and new and improved methods comprising systemic and topical administration of such modulators for the treatment of ocular and dermatological diseases, disorders and conditions, including ocular and dermatological diseases, disorders and conditions characterized at least in part by inflammasome-mediated inflammation.

The present invention relates to compounds and compositions comprising connexin modulators, and their use in dosage regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.

The present invention relates to compounds and compositions comprising connexin modulators, and their use in dose regimens for treating non-healing or persistent defects and disorders of the ocular surface or cornea. In some embodiments, compounds or compositions for the modulation or inhibition of connexins, connexin gap junctions and / or connexin hemichannels are provided for treatment and administered as described herein.

The application discloses a transmembrane transporter of interlinking solap A and an encoding gene and application thereof, and relates to the technical field of microbial genetic engineering. The transmembrane transporter is any one of (1), (2) and (3): (1) a SvMFS1 protein, wherein the amino acid sequence is shown as SEQ ID NO. 3; (2) a protein having more than 90% identity with the SvMFS1 protein and being related to the transport of interlinking solap A, wherein the amino acid sequence of the SvMFS1 protein is subjected to substitution, deletion and / or addition of one or more amino acid residues; and (3) a fusion protein obtained by connecting a protein tag to the N terminal or / and C terminal of (1) or (2). The application researches and finds that the encoding gene of the transmembrane transporter can significantly improve the yield of interlinking solap A when the encoding gene is overexpressed in sacculispora vulgaris, thereby providing a new direction for the development of microbial source interlinking solap A.